Vivos Therapeutics (VVOS) Equity Ratio (2019 - 2026)

Vivos Therapeutics (VVOS) has 8 years of Equity Ratio data on file, last reported at 0.05 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.05, down 111.63% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.05 (down 111.63% YoY), and the FY2025 annual result was 0.06, down 111.84% from the prior year.
• Equity Ratio advanced to 0.05 in Q1 2026 per VVOS's latest filing, from 0.06 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.71 in Q1 2022 and troughed at 0.06 in Q4 2025.
• A 5-year average of 0.28 and a median of 0.35 in 2022 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2024 and 2025: Equity Ratio jumped 11101.71% in 2024, then sank 111.84% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.35 in 2022, then tumbled by 89.05% to 0.04 in 2023, then surged by 1258.65% to 0.52 in 2024, then slumped by 111.84% to 0.06 in 2025, then climbed by 26.26% to 0.05 in 2026.
• Business Quant data shows VVOS's Equity Ratio at 0.05 in Q1 2026, 0.06 in Q4 2025, and 0.1 in Q3 2025.